LUMO Company Profile and Key Details

Lumos Pharma, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.01. This means the shares are trading below this model’s fair value.

The stock is currently mid-range between its 52-week high and low $1.37 and $4.58. With a market capitalization of about $37.54 million, Lumos Pharma, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.33). Key stats such as the average daily volume over the past year has been around 102.98 thousand shares, trading with heavier-than-usual volume. Headquartered in Austin, TX, Lumos Pharma, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Richard J. Hawkins, the company employs approximately 30 people and listed since November 11, 2011. Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases.

Lumos Pharma, Inc. (NASDAQ:LUMO) shares are up 36.48% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Lumos Pharma, Inc. trading at a premium to the broader market with a P/E of -1.04. Analyst sentiment is mixed, with the majority of ratings in Neutral territory and a mean price target of $20.43, suggesting 370.74% upside. Our AI forecast model points to short-term strength (0.23% over two weeks), a medium-term fall (-6.91% over three months), and a longer-term gain (475.81% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Lumos Pharma, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 0.23%, with price expected at $4.35 by December 27, 2024, within a range of $4.32 to $4.38 3-Month Outlook: Projected fall of -6.91%, reaching $4.04 by March 11, 2025, with a range of $3.82 to $4.29. 1-Year Outlook: Projected gain of 475.81%, with price at $24.99 by December 11, 2025, within a range of $24.61 to $31.13.

Lumos Pharma, Inc. trades at a P/E ratio of -1.04, slightly below the S&P 500 average, with a price-to-sales ratio of 18.3 and a price-to-book ratio of 1.29 suggesting the stock is closer to book value. The P/FCF stands at -1.21, also below market averages.